Vasomotor Symptoms of Menopause: Hormonal or Nonhormal Therapy?

the MPR take:

Recent FDA-approved therapies have emerged for treatment of vasomotor symptoms (VMSs) associated with menopause, both hormonal and nonhormonal. A new study in The Annals of Pharmacotherapy evaluated research published between June 2003–May 2014 on the use of paroxetine mesylate (the first nonhormonal therapy FDA-approved for the treatment of VMSs of menopause) or bazedoxifene (BZA)/conjugated estrogens (CEs) for VMSs. Both treatments significantly decreased the incidence of hot flashes vs. placebo. Paroxetine mesylate was not compared head-to-head against BZA/CEs or other hormonal therapies in any of the studies analyzed; however, the authors speculate that the effect on VMSs is less compared to hormone therapy. Both are viable options for VMSs, however, BZA/CEs is only approved for women with an intact uterus.

Hormonal vs. Nonhormonal Menopausal VMSs Txs
Hormonal vs. Nonhormonal Menopausal VMSs Txs

Objective: To review 2 recently approved therapies for vasomotor symptoms (VMSs) of menopause. Data Sources: PubMed searches (June 2003 to May 2014) were conducted using the keywords paroxetine vasomotor and bazedoxifene vasomotor. Studies that evaluated the use of paroxetine mesylate or bazedoxifene (BZA)/conjugated estrogens (CEs) for VMSs were included.